|
Delayed
Nasdaq
14:43:23 12/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 6.249 USD | +1.94% |
|
-1.90% | -6.56% |
| 08-11 | Harvard Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-11 | Harvard Bioscience, Inc., Q2 2026 Earnings Call, Aug 11, 2026 |
Company Valuation: Harvard Bioscience, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 27.65 | - |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | -7.27% | - |
| Enterprise Value (EV) | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 27.65 | 27.65 |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | -7.27% | 0% |
| P/E | -705x | -12x | -66.9x | -7.54x | -0.52x | -3.18x | -15.5x |
| PBR | 3.65x | 1.64x | 3.18x | 1.47x | 2.16x | 4.17x | 5.84x |
| PEG | - | -0x | 1x | -0x | -0x | 0x | 0.2x |
| Capitalization / Revenue | 2.42x | 1.02x | 2.03x | 0.98x | 0.34x | 0.31x | 0.29x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.31x | 0.29x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 3.21x | 2.94x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 4.39x | 3.07x |
| EV / FCF | 0x | -0x | 0x | -0x | 0x | -34.6x | 15.4x |
| FCF Yield | 0.02% | -0.38% | 5.36% | -1.31% | 18.3% | -2.89% | 6.51% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.1 | -2.3 | -0.8 | -2.8 | -12.8 | -1.93 | -0.395 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 118.9 | 113.3 | 112.2 | 94.14 | 86.55 | 89.2 | 93.95 |
| EBITDA 1 | 18.5 | 10.84 | 14.55 | 7.196 | 8.081 | 8.6 | 9.4 |
| EBIT 1 | 16.72 | 9.497 | 13.11 | 5.294 | 6.163 | 6.3 | 9 |
| Net income 1 | -0.288 | -9.516 | -3.415 | -12.4 | -56.7 | -8.8 | -1.85 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 70.500 | 27.700 | 53.500 | 21.100 | 6.688 | 6.130 | 6.130 |
| Nbr of stocks (in thousands) | 4,081 | 4,166 | 4,269 | 4,362 | 4,458 | 4,510 | - |
| Announcement Date | 08/03/22 | 09/03/23 | 07/03/24 | 12/03/25 | 12/03/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.13x | - | - | - | 27.65M | |
| 30.13x | 5.34x | 20.46x | 0.3% | 224B | |
| 34.77x | 6.3x | 19.95x | 0.7% | 146B | |
| 44.02x | 11.48x | 25.38x | -.--% | 142B | |
| 19.14x | 3.88x | 12.61x | -.--% | 74.19B | |
| 37.01x | 7.45x | 23.56x | -.--% | 53.99B | |
| 19.83x | 2.35x | 11.83x | 2.57% | 50.85B | |
| 29.07x | 5.8x | 19.82x | 0.69% | 42.22B | |
| 88.64x | 6.91x | 20.96x | -.--% | 40.75B | |
| 15.58x | 1.79x | 10.01x | 0.22% | 32.86B | |
| Average | 31.51x | 5.70x | 18.29x | 0.5% | 80.61B | |
| Weighted average by Cap. | 34.52x | 6.37x | 19.74x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HBIO Stock
- Valuation Harvard Bioscience, Inc.
Select your edition
All financial news and data tailored to specific country editions
